Dr Michael Morris speaks to ecancer about the health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC.

This trial evaluated lutetium-177 PSMA-617 added to androgen deprivation therapy plus androgen receptor pathway inhibitor therapy in patients with prostate-specific membrane antigen positive metastatic hormone-sensitive prostate cancer.

The combination significantly improved radiographic progression-free survival compared with standard therapy alone.

Despite a modest increase in higher-grade adverse events, there were no meaningful differences in health-related quality of life or pain outcomes, and a trend toward delayed skeletal complications was observed.

These findings support the addition of lutetium-177 PSMA-617 as an effective option that enhances disease control without compromising patient-reported outcomes.